# 2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation

> **NCT04433091** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 95 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** 2-Hydroxybenzylamine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04433091
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-15
- **Primary completion:** 2022-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433091, "2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04433091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*